Governance Protagonist Therapeutics, Inc.

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-05 EST			5-day change	1st Jan Change
89.65 ^USD	+2.66%		-0.39%	+132.25%

11-06	Protagonist Therapeutics Q3 net loss widens to $39.3 mln	RE
11-06	Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q3 Revenue $4.7M, vs. FactSet Est of $3.8M	MT

Executive Committee: Protagonist Therapeutics, Inc.

Manager

Positions heldSince

Dinesh Patel

68 year

Chief Executive Officer	2008-11-30
President	2008-11-30

Matthew M. Gosling

54 year

General Counsel

2020-08-31

Carena Spivey

Human Resources Officer

Mohammad Masjedizadeh

Chief Tech/Sci/R&D Officer

2021-05-31

Asif Ali

51 year

Director of Finance/CFO

2022-04-17

Arturo Molina

66 year

Chief Tech/Sci/R&D Officer

2022-11-06

Newman Yeilding

Chief Tech/Sci/R&D Officer

2025-01-01

Composition of the Board of Directors: Protagonist Therapeutics, Inc.

Director

CommitteesSince

Harold Selick

70 year

Governance Committee
Nominating Committee
Compensation Committee Chair

Bryan Giraudo

49 year

Audit Committee	2021-11-22
Governance Committee Chair
Nominating Committee Chair
Compensation Committee	2021-11-22
Nominating Committee	2021-11-22

William Waddill

68 year

Compensation Committee	2017-12-31
Audit Committee Chair	2021-08-11
Nominating Committee
Governance Committee

Sarah O'Dowd

75 year

Audit Committee	2024-09-18
Governance Committee
Nominating Committee

Lewis Williams

75 year

Compensation Committee

Dinesh Patel

68 year

Director/Board Member

2008-11-30

Latest Appointments: Protagonist Therapeutics, Inc.

01-06	Protagonist Therapeutics, Inc. Appoints Newman Yeilding as Executive Vice President, Chief Scientific Officer	CI
01-06	Protagonist Therapeutics, Inc. Announces Transition of Suneel Gupta from Chief Development Officer to Executive Vice President, Clinical Development	CI
24-09-20	Protagonist Therapeutics, Inc. Announces Board Changes	CI
24-07-31	Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024	CI
23-10-30	Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director	CI
23-07-03	Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director	CI
23-01-06	Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor	CI

More news

Former Officers and Directors: Protagonist Therapeutics, Inc.

Insider

Positions held

SinceUntil

Daniel Swisher

Director/Board Member

2023-10-25

2024-09-16

Craig Ostroff

General Counsel

2022-06-30

2024-06-30

Scott Plevy

Corporate Officer/Principal

2021-09-06

2024-02-29

Jami Taylor

Investor Relations Contact	2021-02-28	2023-10-31
Public Communications Contact	2021-02-28	2023-10-31

Sarah Noonberg

Director/Board Member	2017-12-13	2023-05-24
Independent Dir/Board Member	2017-12-13	2023-05-24

David Liu

Chief Tech/Sci/R&D Officer

2013-05-29

2022-12-31

Tracy Woody

Corporate Officer/Principal

2020-03-31

2022-08-31

Paula O’Connor

Chief Tech/Sci/R&D Officer

2022-08-31

Mark L. Smythe

Chief Tech/Sci/R&D Officer	2006-08-21	2022-04-30
Founder	2006-08-21	2022-04-30

Donald Kalkofen

Comptroller/Controller/Auditor	2019-05-27	2022-03-31
Director of Finance/CFO	2019-05-27	2022-03-31

Arjun Agarwal

Comptroller/Controller/Auditor

2019-07-31

2021-05-31

Chaitan Khosla

Director/Board Member	2014-09-30	2020-08-10
Independent Dir/Board Member	2014-09-30	2020-08-10

Armen Shanafelt

Director/Board Member

2009-12-31

2019-05-31

Richard S. Shames

Chief Tech/Sci/R&D Officer

2015-07-31

2019-05-08

Lucio Tozzi

Chief Tech/Sci/R&D Officer

2015-06-30

2019-04-30

Niall Murphy

Comptroller/Controller/Auditor

2018-08-14

2019-03-18

Thomas O'Neil

Comptroller/Controller/Auditor	2016-02-16	2019-01-10
Director of Finance/CFO	2016-02-16	2019-01-10

Julie Grant

Director/Board Member	2015-07-15	2017-12-13
Independent Dir/Board Member	2015-07-15	2017-12-13

Thamil Annamalai

Corporate Officer/Principal

2013-12-31

2016-12-31

Asish Xavier

Director/Board Member

2012-12-31

2015-12-31

William Hodder

Corporate Officer/Principal

2014-12-17

Patricia A. Murphy

General Counsel

2013-12-31

Tran Trung Tran

Corporate Officer/Principal

Kathy Nielsen

Director/Board Member

Bryan Dunnivant

Director/Board Member

Nick Peace

Director/Board Member

Paul Truex

Director/Board Member	-	-
Independent Dir/Board Member	-	-

David Pugatch

Chief Tech/Sci/R&D Officer

Larry Mattheakis

Corporate Officer/Principal

Bittoo Kanwar

Chief Tech/Sci/R&D Officer

Michael Panaccio

Director/Board Member

Gregory T. Bourne

Corporate Officer/Principal

Craig Murphy

Chief Tech/Sci/R&D Officer	2013-03-05	-
Corporate Officer/Principal	-	2013-03-05

Age distribution of managers

Parity Men Women

Male	14
Female	2

Of which Executive Committee

Male	6
Female	1

Of which Directors

Male	5
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (Î±4Î²7) specific integrin antagonist for inflammatory bowel disease (IBD).

Employees

128

Sector

Biotechnology & Medical Research

Calendar

10:00am - American Society of Hematology Meeting - Publication Number: 81

More about the company